专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5045239A Non-linear optical material 失效
标题翻译：非线性光学材料
公开(公告)号：US5045239A
公开(公告)日：1991-09-03
申请号：US362464
申请日：1989-03-17
申请人： Seizo Miyata , Toshiyuki Watanabe , Yoshitaka Goto , Akio Hayashi , Masaharu Nakayama
发明人： Seizo Miyata , Toshiyuki Watanabe , Yoshitaka Goto , Akio Hayashi , Masaharu Nakayama
IPC分类号： G02F1/361
CPC分类号： G02F1/3613
摘要： A non-linear optical material comprises a derivative of chalcone represented by the following general formulae (I) or (II) of: ##STR1## wherein R.sub.1 and R.sub.2 each represent a halogen atom, a hydroxyl group, an amino group, a dimethylamino group, a nitro group, a cyano group, a phenyl group, an acetyl group, an alkyl group having 1 to 18 carbon atoms or an alkyloxy group having 1 to 22 carbon atoms; n.sub.1 and n.sub.2 each represent an interger of from 0 to 21; and m.sub.1 and m.sub.2 each represent an integer of from 0 to 5.
摘要翻译： PCT No.PCT / JP88 / 00740 Sec。 371日期：1989年3月17日 102（e）日期1989年3月17日PCT提交1988年7月22日PCT公布。出版物WO89 / 01181 日期：1989年2月9日。非线性光学材料包含由以下通式（I）或（II）表示的查耳酮衍生物：其中R 1和R 2各自表示卤素原子，羟基，氨基，二甲基氨基，硝基，氰基，苯基，乙酰基，碳原子数1〜18的烷基或具有1〜22个的烷氧基的烷基碳原子 n1和n2分别表示从0到21的整数; m1和m2各自表示0〜5的整数。

2. 发明授权

US4892681A Non-linear optical article 失效
标题翻译：非线性光学制品
公开(公告)号：US4892681A
公开(公告)日：1990-01-09
申请号：US102193
申请日：1987-09-29
申请人： Seizo Miyata , Toshiyuki Watanabe , Yoshitaka Goto , Masaharu Nakayama
发明人： Seizo Miyata , Toshiyuki Watanabe , Yoshitaka Goto , Masaharu Nakayama
IPC分类号： C07C49/76 , C07C45/00 , C07C45/74 , C07C49/796 , C07C49/813 , C07C49/84 , C07C67/00 , C07C213/00 , C07C225/22 , G02F1/35 , G02F1/355 , G02F1/361
CPC分类号： G02F1/3611 , C07C45/74 , C07C49/796 , C07C49/813 , C07C49/84
摘要： A non-linear optical article is constituted of a derivative of benzalacetophenone represented by the following general formula: ##STR1## wherein A and B each represent the same or different atom or group and stand for a hydrogen atom, an alkoxy group having 1 to 4 carbon atoms, a chlorine atom, a bromine atom, an amino group or a dialkylamino group having 1 to 2 carbon atoms.

3. 发明授权

US5144044A Non-linear optical material and non-linear optical device 失效
标题翻译：非线性光学材料和非线性光学器件
公开(公告)号：US5144044A
公开(公告)日：1992-09-01
申请号：US586756
申请日：1990-09-24
申请人： Yoshitaka Goto , Masaharu Nakayama
发明人： Yoshitaka Goto , Masaharu Nakayama
IPC分类号： G02F1/35 , C07D333/22 , C09K9/02 , G02F1/355 , G02F1/361
CPC分类号： G02F1/3614 , C07D333/22
摘要： A non-linear optical material consists essentially of 3-(2-thienyl)-1-(4-methylphenyl)propene-3-one represented by the formula (I) ##STR1## A non-linear optical device contains an organic compound disposed in a light beam. The organic compound is represented by the formula (I) and has a crystal in which a space group determined by the X-ray analytical method is P2.sub.1.

4. 发明授权

US5100584A Non-linear optical device 失效
标题翻译：非线性光学器件
公开(公告)号：US5100584A
公开(公告)日：1992-03-31
申请号：US629147
申请日：1990-12-18
申请人： Yoshitaka Goto , Zhang G. Jian , Masaharu Nakayama
发明人： Yoshitaka Goto , Zhang G. Jian , Masaharu Nakayama
IPC分类号： G02F1/35 , C07D307/46 , G02F1/355 , G02F1/361
CPC分类号： C07D307/46 , G02F1/3611 , G02F1/3613
摘要： A non-linear optical device is provided in which an organic compound is disposed in a light beam. The organic compound is a benzalacetofuran derivative represented by the following formula (I) ##STR1## wherein R is CH.sub.3, CH.sub.3 S, Br, CN or NO.sub.2.

5. 发明申请

US20110105940A1 METHOD FOR QUANTIFICATION OF TITER OF NEUTRALIZING ANTIBODY TO NEUROTOXIN 审中-公开
标题翻译：中性抗体对神经毒素的定量的方法
公开(公告)号：US20110105940A1
公开(公告)日：2011-05-05
申请号：US12673980
申请日：2008-08-20
申请人： Yasushi Torii , Tetsuhiro Harakawa , Yoshitaka Goto , Akihiro Ginnaga , Ryuji Kaji , Shunji Kozaki , Motohide Takahashi
发明人： Yasushi Torii , Tetsuhiro Harakawa , Yoshitaka Goto , Akihiro Ginnaga , Ryuji Kaji , Shunji Kozaki , Motohide Takahashi
IPC分类号： A61B5/0488
CPC分类号： G01N33/6854 , A61B5/0488 , G01N2333/33 , G01N2469/20
摘要： A method for quantification of a titer of a neutralizing antibody to a neurotoxin is disclosed. The method comprises the steps: (a) mixing a standard sample containing a fixed amount of a neurotoxin and a test sample containing a neutralizing antibody to said neurotoxin; (b) administering the mixture obtained in step (a) into the muscle of a non-human mammal; (c) applying electric stimulus to said non-human mammal; (d) measuring a compound muscle action potential (CMAP) due to contraction of the muscle of said mammal by application of electric stimulus with an electromyograph; and (e) analyzing CMAP amplitude data obtained in step (d) for an extent of decrease in amplitude by a non-neutralized neurotoxin to thereby quantify a titer of the neutralizing antibody contained in the test sample.
摘要翻译：公开了定量神经毒素中和抗体滴度的方法。该方法包括以下步骤：（a）将含有固定量的神经毒素的标准样品和含有中和抗体的测试样品与所述神经毒素混合; （b）将步骤（a）中获得的混合物给予非人哺乳动物的肌肉; （c）对所述非人哺乳动物施加电刺激; （d）通过用肌电图仪施加电刺激来测量由于所述哺乳动物的肌肉收缩引起的复合肌肉动作电位（CMAP）; 和（e）通过未中和的神经毒素分析在步骤（d）中获得的CMAP振幅数据的幅度减小，从而定量测试样品中所含的中和抗体的滴度。

6. 发明申请

US20110033431A1 TYPE A2 BOTULINUM TOXIN PREPARATION 审中-公开
标题翻译： A2型BOTULINUM毒素制剂
公开(公告)号：US20110033431A1
公开(公告)日：2011-02-10
申请号：US12935769
申请日：2009-03-31
申请人： Shinji Nakahira , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Satomi Munechika , Sachio Okuda , Shunji Kozaki
发明人： Shinji Nakahira , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Satomi Munechika , Sachio Okuda , Shunji Kozaki
IPC分类号： A61K35/74 , A61P21/00 , C12N1/20 , C07K14/33
CPC分类号： A61K38/164 , A61K38/4893 , Y02A50/469
摘要： A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a botulinum toxin from type A1 Clostridium botulinum (type A1 botulinum toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX); a medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1 botulinum toxin, said medicament comprising as an active ingredient said A2 NTX; a method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering said A2 NTX to the patient; and a method for use of A2 NTX in a patient who has said neutralizing antibody. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation comprising a type A1 botulinum toxin.
摘要翻译：一种用于患有来自A1型肉毒毒素（A1型肉毒杆菌毒素）的肉毒毒素中和抗体的患者的药物制剂，所述制剂包含来自A2型肉毒毒素（A2NTX）的150kDa A型神经毒素作为活性成分， ; 用于治疗患有肌肉过度活动的疾病的药物，所述疾病用于患有A1型肉毒杆菌毒素的中和抗体的患者，所述药物包含所述A2NXX的活性成分; 用于治疗对A1型肉毒杆菌毒素具有中和抗体的患者的方法，所述方法包括向患者施用所述A2NXX; 以及在具有所述中和抗体的患者中使用A2NTX的方法。根据本发明，当患者用包含A1型肉毒杆菌毒素的药物制剂治疗时，可以解决由中和抗体对产生的A1型肉毒杆菌毒素引起的临床反应降低的问题。

7. 发明申请

US20100173841A1 Highly Purified Type A Botulinum Toxin Preparation From Infant Botulism Pathogen 有权
标题翻译：高纯度A型肉毒杆菌毒素从婴儿肉毒杆菌病原体制备
公开(公告)号：US20100173841A1
公开(公告)日：2010-07-08
申请号：US12447351
申请日：2007-10-26
申请人： Tetsuhiro Harakawa , Hirotoshi Nakano , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Sachio Okuda , Ryuji Kaji , Shunji Kosaki
发明人： Tetsuhiro Harakawa , Hirotoshi Nakano , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Sachio Okuda , Ryuji Kaji , Shunji Kosaki
IPC分类号： A61K38/16 , C07K14/33 , A61P25/06 , A61P13/10 , A61P25/14 , A61P25/00 , A61P21/00 , A61P29/00
CPC分类号： A61K47/42 , A61K9/0019 , A61K9/19 , A61K38/4893 , Y02A50/469
摘要： A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.
摘要翻译：提供了一种新型的A型肉毒杆菌毒素制剂。一种包含作为活性成分的来自肉毒梭菌的高度纯化的A型肉毒杆菌毒素作为婴儿肉毒杆菌病原体的神经肌肉阻滞剂和用于治疗肌肉过度活动的疾病的药物，其包含所述毒素作为活性成分。特别地，与常规已知的肉毒杆菌毒素制剂相比，本发明的药物具有快速的潜力和较少的扩散作用，因此具有较宽的安全性，可用作减少局部，肌肉过度活动的治疗药物在肌肉过度活动的疾病中。

8. 发明授权

US06254973B1 Fluorine-containing polyfunctional (meth) acrylate, fluorine containing monomer composition, low refractivity material, and reflection reducing film 失效
$Fluorine-containing polyfunctional (meth) acrylate, fluorine containing monomer composition, low refractivity material, and reflection reducing film$
标题翻译：含氟多官能（甲基）丙烯酸酯，含氟单体组合物，低折射率材料和反射还原膜
公开(公告)号：US06254973B1
公开(公告)日：2001-07-03
申请号：US08945228
申请日：1997-10-10
申请人： Tatsurou Yoshida , Yasuhiro Kimura , Kenji Watanabe , Tomoyuki Ikeda , Tetsuya Itoh , Yoshitaka Goto
发明人： Tatsurou Yoshida , Yasuhiro Kimura , Kenji Watanabe , Tomoyuki Ikeda , Tetsuya Itoh , Yoshitaka Goto
IPC分类号： B32B2730
CPC分类号： C08F222/1006 , C07C69/653 , C08F22/105 , Y10T428/24942 , Y10T428/3154
摘要： Fluorine-containing polyfunctional (meth)acrylate represented by the formula (1), a monomer composition containing the (meth)acrylate, a low refractivity material prepared by curing the monomer composition, and a reflection reducing film provided with the low refractivity material. wherein R1, R2, R3, and R4 are the same or different groups, and each stands for a hydrogen atom, an acryloyl group, or a methacryloyl group, at least one of R1 and R2 and at least one of R3 and R4 stand for an acryloyl group or a methacryloyl group, R stands for a fluoroalkylene group having 2 to 12 carbon atoms and 2 or more fluorine atoms.
摘要翻译：由式（1）表示的含氟多官能（甲基）丙烯酸酯，含有（甲基）丙烯酸酯的单体组合物，通过固化单体组合物制备的低折射率材料和设置有低折射率材料的反射率降低膜。 R1，R2，R3和R4是相同或不同的基团，各自代表氢原子，丙烯酰基或甲基丙烯酰基，R 1和R 2中的至少一个和R 3和R 4中的至少一个代表丙烯酰基或甲基丙烯酰基，R表示碳原子数2〜12，氟原子数2以上的氟代亚烷基。

9. 发明授权

US6087010A Fluorine-containing polyfunctional (meth) acrylate composition low refractivity material and reflection reducing film 失效
$Fluorine-containing polyfunctional (meth) acrylate composition low refractivity material and reflection reducing film$
标题翻译：含氟多官能（甲基）丙烯酸酯组合物低折射率材料和反射降低膜
公开(公告)号：US6087010A
公开(公告)日：2000-07-11
申请号：US11812
申请日：1998-02-09
申请人： Tatsurou Yoshida , Yasuhiro Kimura , Kenji Watanabe , Tomoyuki Ikeda , Tetsuya Itoh , Yoshitaka Goto
发明人： Tatsurou Yoshida , Yasuhiro Kimura , Kenji Watanabe , Tomoyuki Ikeda , Tetsuya Itoh , Yoshitaka Goto
IPC分类号： B32B27/00 , C07C69/52 , C07C69/66 , C08F18/20
CPC分类号： B32B27/00 , C07C69/52 , C07C69/66 , C08F18/20
摘要： Fluorine-containing polyfunctional (meth)acrylate represented by the formula (1), as well as a composition, a low refractivity material and a reflection reducing film in which the (meth)acrylate is utilized: ##STR1## wherein X stands for a fluoroalkyl group of C1-14 having 3 or more F, or a fluorocycloalkyl group of C3-14 having 4 or more F; Y.sup.1, Y.sup.2, and Y.sup.3 stand for H, an acryloyl group or a methacryloyl group, and at least two of Y.sup.1, Y.sup.2, and Y.sup.3 stand for an acryloyl group or a methacryloyl group; Z stands for H or an alkyl group of C1-3; and n and m is an integer of 0 or 1, and n+m=1.
摘要翻译： PCT No.PCT / JP97 / 01952 Sec。 371日期：1998年2月9日 102（e）1998年2月9日PCT PCT 1997年6月9日PCT公布。第WO97 / 47585号公报日期：1997年12月18日由式（1）表示的含氟多官能（甲基）丙烯酸酯以及其中使用（甲基）丙烯酸酯的组合物，低折射率材料和反射还原膜：其中X代表具有3个或更多个F的C1-14的氟代烷基或具有4个或更多个F的C3-14的氟代环烷基; Y 1，Y 2和Y 3表示H，丙烯酰基或甲基丙烯酰基，Y1，Y2和Y3中的至少两个表示丙烯酰基或甲基丙烯酰基; Z代表H或C 1-3的烷基; n和m为0或1的整数，n + m = 1。

10. 发明授权

US09623075B2 Type A2 botulinum toxin preparation 有权
公开(公告)号：US09623075B2
公开(公告)日：2017-04-18
申请号：US13903731
申请日：2013-05-28
申请人： Shinji Nakahira , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Satomi Munechika , Sachio Okuda , Shunji Kozaki
发明人： Shinji Nakahira , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Satomi Munechika , Sachio Okuda , Shunji Kozaki
IPC分类号： A61K38/48 , A61K38/16
CPC分类号： A61K38/164 , A61K38/4893 , Y02A50/469
摘要： A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式